Gene Therapy for Subjects With RPGR Mutation-associated X-linked Retinitis Pigmentosa
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT05874310 |
Recruitment Status :
Recruiting
First Posted : May 24, 2023
Last Update Posted : May 24, 2023
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
X-Linked Retinitis Pigmentosa | Genetic: FT-002 | Early Phase 1 |
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 18 participants |
Allocation: | Non-Randomized |
Intervention Model: | Sequential Assignment |
Intervention Model Description: | X-linked retinitis pigmentosa patients |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | An Open-label, Single-center, Dose-escalation Clinical Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of Intraocular Administration of FT-002 in Subjects With RPGR Mutation-associated X-linked Retinitis Pigmentosa. |
Actual Study Start Date : | February 1, 2023 |
Estimated Primary Completion Date : | October 31, 2023 |
Estimated Study Completion Date : | November 1, 2027 |
Arm | Intervention/treatment |
---|---|
Experimental: Low dose FT-002
Intraocular injection of a single low dose of FT-002
|
Genetic: FT-002
Comparison of different dosages of FT-002 |
Experimental: Intermediate dose FT-002
Intraocular injection of a single Intermediate dose of FT-002
|
Genetic: FT-002
Comparison of different dosages of FT-002 |
Experimental: High dose FT-002
Intraocular injection of a single High dose of FT-002
|
Genetic: FT-002
Comparison of different dosages of FT-002 |
- Incidence of AEs [ Time Frame: from FT-002 administration through up to 1 years ]Number and proportion of Adverse Events
- Change in visual function [ Time Frame: from FT-002 administration through up to 1 years ]Change in retinal function as assessed by mean retinal sensitivity within the 30-degree visual field
- Change in retinal structure as assessed by Optical Coherence Tomography [ Time Frame: from FT-002 administration through up to 1 years ]Change in Outer Nuclear Layer Thickness from baseline as assessed by Optical Coherence Tomography
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 8 Years to 45 Years (Child, Adult) |
Sexes Eligible for Study: | Male |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
1.Subjects that are willing and able to follow study procedures; 2.Males aged 8-45 years old at the time of signing the Informed Consent Form; 4.Subjects who are confirmed with variants of RPGR ;
Exclusion Criteria:
1.Have other retinal degenerative diseases, such as retinal degeneration caused by other known Inherited retinal disease gene variants or previously received an gene therapy product.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05874310
Contact: Xinyan Li | +86-021-58206061 | xinyan.li@fronteratherapeutics.com | |
Contact: Minghui Xue | +86-021-58206061 | minghui.xue@fronteratherapeutics.com |
China, Beijing | |
Peking Union Medical College Hospital | Recruiting |
Beijing, Beijing, China, 100142 | |
Contact: Ruifang Sui, Professor | |
China, Shanghai | |
Eye & ENT hospital of Fudan university | Recruiting |
Shanghai, Shanghai, China, 200032 | |
Contact: Gezhi Xu, Professor | |
Contact: Jihong Wu, Professor |
Principal Investigator: | Gezhi Xu | Eye & ENT Hospital of Fudan University | |
Principal Investigator: | Ruifang Sui | Peking Union Medical College Hospital |
Responsible Party: | Frontera Therapeutics |
ClinicalTrials.gov Identifier: | NCT05874310 |
Other Study ID Numbers: |
FT002RP-1 |
First Posted: | May 24, 2023 Key Record Dates |
Last Update Posted: | May 24, 2023 |
Last Verified: | August 2022 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Plan Description: | Researchers qualified can request the dataset, including de-identified individual subject data. |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
Retinitis Retinitis Pigmentosa Retinal Diseases Eye Diseases |
Eye Diseases, Hereditary Retinal Dystrophies Retinal Degeneration Genetic Diseases, Inborn |